1) Nobody said Celgene has left the table.
2) No suggestion Teva are about to walk away - they have in fact, had that "right" for years and have only instead, spent many more millions of dollars progressing - "excellently" - the CHF PhIII. This issue was specifically raised TODAY with the Prof!
3) I suspect we're "close" to a number of very significant announcements, the Prof said as much a couple of hours ago ie, he said, some version of "I look forward to making announcements soon"! I don't know if that means a couple of days, a week, a month....but every day it gets closer. Frankly, I've never cared too much about an hour-by-hour assessment of it all - again, we're not retailing cans of Coke at 30% OFF today only - we're in a very serious business, with considerable time-frames!!
4) The Independent CHF Study review committee, has basically given the CHF a big GREEN tick - frankly, I'm stunned the market has not gone in reverse - ie, UP! These are independent experts, with hands-on oversight of the study and they are pleased to see it continue. It only means two things 1) No safety issues 2) Likely benefits for participants receiving MSB product. Beyond that, no-one rightly knows to protect the integrity of the study.
Highlights:
Japan - Temcell
Japan - potential for other products
Harvard technology - the sky's the limit
Back pain progressing - partner likely, clear run to market IMO
RA/Diabetes, at the starters gate for PhIII - should be announcements this year - see Harvard comments
The BIG downer - it all takes time and no-one, including the Prof can just shoot from the hip - all statements must be considered......you can at times sense his "frustration"......but that's life.
I do think he [the Prof] could have gone a little more on the front foot over Celgene and simply said something like "we continue in good dialogue with a number of potential partners, some on the public record and others and remain positive as to what will achieved in due course".
That would have headed off most peoples minds running wild, with largely imaginary negatives. more one could say....but no real point!
- Forums
- ASX - By Stock
- MSB
- Assessment of todys presentation
Assessment of todys presentation, page-2
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B |
Open | High | Low | Value | Volume |
$1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 23940 | $1.39 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.40 | 22571 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 13940 | 1.390 |
1 | 14000 | 1.385 |
2 | 15350 | 1.370 |
2 | 20000 | 1.355 |
2 | 2400 | 1.350 |
Price($) | Vol. | No. |
---|---|---|
1.395 | 22571 | 2 |
1.400 | 108300 | 3 |
1.405 | 39000 | 3 |
1.410 | 1430 | 1 |
1.415 | 67966 | 3 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online